Identification of dermatophytes by MALDI-TOF MS technology in the clinical laboratory

2019 ◽  
Vol 440 ◽  
pp. 32-36 ◽  
Author(s):  
Maya Azrad ◽  
Victoria Freidus ◽  
Riad Kassem ◽  
Avi Peretz
Keyword(s):  
Clinical Laboratory ◽  
Maldi Tof Ms ◽  
Maldi Tof ◽  
Tof Ms

scholarly journals Evaluation of the system Axima/Saramis MALDI-TOF MS bioMérieux in a clinical laboratory

2012 ◽  
Vol 27 (1) ◽  
Author(s):  
Romano Mattei ◽  
Claudia Vicario ◽  
Maria Nardone ◽  
Arnaldo Savarino
Keyword(s):  
Clinical Laboratory ◽  
Maldi Tof Ms ◽  
Maldi Tof ◽  
Tof Ms

S1. A modified method for blood culture direct testing using 2% SDS detergent and heat. v1

2021 ◽  
Author(s):  
kwenrich not provided
Keyword(s):  
Blood Culture ◽  
Clinical Laboratory ◽  
Sodium Dodecyl ◽  
Agar Plate ◽  
Drying Methods ◽  
Maldi Tof Ms ◽  
Maldi Tof ◽  
Modified Method ◽  
Flight Mass Spectrometry ◽  
Tof Ms

Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) can accurately identify bloodstream pathogens directly from positive blood culture bottles without the need to wait for agar plate growth. In this study, 2% sodium dodecyl sulfate (SDS) detergent was assessed to determine its benefit in the removal of interfering cellular components for testing on the Bruker Microflex LT MALDI-TOF MS instrument with the Biotyper® CA system. Additionally, the use of a heat-drying step was evaluated for performance improvement over conventional air-drying of samples on the MALDI steel target plate. The modified method with 2% SDS outperformed the in-house protocol in overall success with percentage scores of 91% and 55% ( respectively). The data results support the potential of applying a simple lysing step to an existing in-house extraction method and the use of modified drying methods. The modified techniques evaluated in this study proved beneficial for identifying most blood culture pathogens encountered in the clinical laboratory, and they can allow for reduced turnaround times and more appropriate antibiotic treatments.

MALDI-TOF MS: Its Application in the Clinical Laboratory and a Paradigm Shift in Clinical Microbiology

2015 ◽  
Vol 5 (4) ◽  
pp. 176 ◽  
Author(s):  
Taek Soo Kim ◽  
Kyunghoon Lee ◽  
Yun Ji Hong ◽  
Sang Mee Hwang ◽  
Jeong Su Park ◽  
...  
Keyword(s):  
Paradigm Shift ◽  
Clinical Microbiology ◽  
Clinical Laboratory ◽  
Maldi Tof Ms ◽  
Maldi Tof ◽  
Tof Ms

scholarly journals Development and Validation of an In-House Library for Filamentous Fungi Identification by MALDI-TOF MS in a Clinical Laboratory in Medellin (Colombia)

2020 ◽  
Vol 8 (9) ◽  
pp. 1362
Author(s):  
Juan C. Gómez-Velásquez ◽  
Natalia Loaiza-Díaz ◽  
Gilma Norela Hernández ◽  
Nelson Lima ◽  
Ana C. Mesa-Arango
Keyword(s):  
Filamentous Fungi ◽  
Clinical Laboratory ◽  
Species Level ◽  
Clinical Isolates ◽  
Correct Identification ◽  
Maldi Tof Ms ◽  
Genus Level ◽  
Maldi Tof ◽  
Fungal Identification ◽  
Tof Ms

Identification of filamentous fungi by conventional phenotypic methods are time-consuming, and a correct identification at the species level is prone to errors. Therefore, a more accurate and faster time-to-results, and cost-effective technique, is required, such as the Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS). In this study, we describe the development of an in-house spectra library for the identification of filamentous fungi frequently isolated from patients with infections. An in-house spectra library was constructed using 14 reference strains grown in solid medium. Clinical isolates were identified either by the in-house spectra library or the Biotyper commercial library from Bruker Daltonics. Fungal identification was carried following the Biotyper’s established scores: ≤1.699: not reliably identified (NRI); 1.700–1.999: genus-level; ≥2.000: species-level. Clinical isolates were identified, with the in-house library, at species- and genus-level at 88.70% (55) and 3.22% (2), respectively. While 4.80% (3) was NRI and 3.22% (2) was discrepant concerning sequencing. On the contrary, identification up to species and genus-level with the commercial library was 44.44% (16) and 22.22% (8), respectively. NRI and the discrepancy was 30.55% (11) and 2.77% (1), respectively. For the reaming 26 isolates, 16 from Neoscytalidium dimidiatum and 10 from Sporothrix spp., respectively, the absence of spectrum and the specific spectra within the Sporothrix complex in the commercial library resulted in the inability to obtain an identification. In conclusion, the current results advocate the importance that each clinical microbiological laboratory needs to develop an ad hoc library associated with the MALDI-TOF MS fungal identification to overcome the limitations of the available commercial libraries.

scholarly journals Evaluation of four pretreatment procedures for MALDI-TOF MS yeast identification in the routine clinical laboratory

2013 ◽  
Vol 51 (4) ◽  
pp. 371-377 ◽  
Author(s):  
Carole Cassagne ◽  
Anne-Laure Cella ◽  
Pierre Suchon ◽  
Anne-Cecile Normand ◽  
Stephane Ranque ◽  
...  
Keyword(s):  
Clinical Laboratory ◽  
Yeast Identification ◽  
Maldi Tof Ms ◽  
Maldi Tof ◽  
Routine Clinical Laboratory ◽  
Tof Ms

Clinical Validation of a 106-SNV MALDI-ToF MS Pharmacogenomic Panel

2020 ◽  
Vol 5 (3) ◽  
pp. 454-466
Author(s):  
Grace R Williams ◽  
Leanne Cook ◽  
Lionel D Lewis ◽  
Gregory J Tsongalis ◽  
Robert D Nerenz
Keyword(s):  
Drug Response ◽  
Clinical Laboratory ◽  
Cost Effective ◽  
Accurate Method ◽  
Care Providers ◽  
Maldi Tof Ms ◽  
Maldi Tof ◽  
Assay Precision ◽  
Custom Panel ◽  
Tof Ms

Abstract Background Laboratorians have the opportunity to help minimize the frequency of adverse drug reactions by implementing pharmacogenomic testing and alerting care providers to possible patient/drug incompatibilities before drug treatment is initiated. Methods combining PCR with MALDI-ToF MS have allowed for sensitive, economical, and multiplexed pharmacogenomic testing results to be delivered in a timely fashion. Method This study evaluated the analytical performance of the Agena Biosciences iPLEX® PGx 74 panel and a custom iPLEX panel on a MassARRAY MALDI-TOF MS instrument in a clinical laboratory setting. Collectively, these panels evaluate 112 SNVs across 34 genes implicated in drug response. Using commercially available samples (Coriell Biorepository) and in-house extracted DNA, we determined ideal reaction conditions and assessed accuracy, precision, and robustness. Results Following protocol optimization, the Agena PGx74 and custom panels demonstrated 100% concordance with the 1000 Genomes Project Database and clinically validated hydrolysis probe genotyping assays. 100% concordance was also observed in all assessments of assay precision when appropriate QC metrics were applied. Conclusions Significant development time was required to optimize sample preparation and instrumental analysis and 3 assays were removed due to inconsistent performance. Following modification of the manufacturer’s protocol and instituting manual review of each assay plate, the Agena PGx74 and custom panel constitute a cost-effective, robust, and accurate method for clinical identification of 106 SNVs involved in drug response.

scholarly journals A diagnostic challenge in clinical laboratory: Misidentification of Neisseria subflava as Neisseria meningitidis by MALDI-TOF MS

2020 ◽  
pp. 1-3
Author(s):  
Tugce Unalan-Altintop ◽  
Alper Karagoz ◽  
Gulsen Hazirolan
Keyword(s):  
Neisseria Meningitidis ◽  
Clinical Laboratory ◽  
Cost Effective ◽  
Diagnostic Challenge ◽  
Accurate Identification ◽  
Maldi Tof Ms ◽  
Maldi Tof ◽  
Neisseria Subflava ◽  
Effective Diagnosis ◽  
Tof Ms

Abstract MALDI-TOF MS provides fast, easy to perform and cost-effective diagnosis in clinical microbiology laboratories, however in some cases results of MALDI-TOF MS should be confirmed with additional tests. This confirmation is especially important for causes of life-threatening infections like Neisseria meningitidis. In our laboratory, three isolates were identified as N. meningitidis by Bruker MALDI Biotyper (BD, USA) between April 2018 and March 2019 from clinical specimens of blood, sputum, and urine. 16S rRNA sequencing was performed for further investigation. Two of the isolates were identified as Neisseria subflava and only one was confirmed as N. meningitidis by sequencing. These results show that MALDI-TOF MS is not always reliable in the diagnosis of N. meningitidis and clinical microbiologists should confirm these results with additional tests. Also, clinical correlations should be determined. Accurate identification of this microorganism is very important because of the necessity of prophylactic antimicrobial usage and biosafety precautions. Enlarged databases of Neisseria species are needed to overcome this problem.

895: Proteomic Analysis of Sera from Bladder Cancer Patients with MALDI-TOF-MS

2007 ◽  
Vol 177 (4S) ◽  
pp. 297-297
Author(s):  
Kristina Schwamborn ◽  
Rene Krieg ◽  
Ruth Knüchel-Clarke ◽  
Joachim Grosse ◽  
Gerhard Jakse
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Proteomic Analysis ◽  
Maldi Tof Ms ◽  
Maldi Tof ◽  
Tof Ms
Sign in / Sign up

Export Citation Format

Share Document